Faye Su
YOU?
Author Swipe
View article: Integrating multi-omics data to reveal the host-microbiota interactome in inflammatory bowel disease
Integrating multi-omics data to reveal the host-microbiota interactome in inflammatory bowel disease Open
Numerous studies have accelerated the knowledge expansion on the role of gut microbiota in inflammatory bowel disease (IBD). However, the precise mechanisms behind host-microbe cross-talk remain largely undefined, due to the complexity of …
View article: The Effect of Maternal Obesity on Placental Autophagy in Lean Breed Sows
The Effect of Maternal Obesity on Placental Autophagy in Lean Breed Sows Open
This study aimed to evaluate the influence of back-fat thickness (BF), at mating of sows, on autophagy in placenta and the potential mechanism. The sows were divided into two groups according to their BF at mating: BFI (15–20 mm, n = 14) a…
View article: Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study
Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study Open
Objective: This study investigates the development trends and research hotspots in clinical testing for multiple myeloma from 2000 to 2023, using bibliometric techniques. Method: Search for relevant literature on clinical testing of multip…
View article: Impact of an extended light regimen imposed during nursery period on the performance and lipid metabolism of weanling pigs
Impact of an extended light regimen imposed during nursery period on the performance and lipid metabolism of weanling pigs Open
Objective: This study aimed to assess the impact of a prolonged photoperiod on the growth performance and lipid metabolism of weaned piglets.Methods: Twenty-four piglets weaned at 28 days of age were randomly dichotomized into two groups t…
View article: Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials Open
NCT01958021, NCT02422615, NCT02278120.
View article: TP030/#1426 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline BRCA mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer
TP030/#1426 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline BRCA mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer Open
Objectives High-grade serous ovarian cancer (HGSOC) represents most epithelial ovarian cancers. Whilst initially responding to platinum-based therapy, ~75% of patients develop resistance, conferring poor prognosis. Homologous recombination…
View article: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer Open
Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i), combined with endocrine therapy (ET), have demonstrated higher antitumor activity than ET alone for the treatment of advanced estrogen receptor-positive (ER+) breast cancer (BC). Some …
View article: Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer Open
Background Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2− breast cancer. However, acquired resistance to these therapies frequently leads to disease progression. As such, it is critical…
View article: Additional file 9 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Additional file 9 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer Open
Additional file 9: Table S6–18. Mean tumor volumes and mouse body weights from each of the xenograft studies presented in this manuscript.
View article: Additional file 4 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Additional file 4 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer Open
Additional file 4: Table S1. Table listing Ribociclib IC50 in each of the breast cancer cell lines. ER, AR and HER2 levels, as measured by RPPA, also included for reference.
View article: Additional file 7 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Additional file 7 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer Open
Additional file 7: Table S4. Mean mouse body weights in each of the experimental arms (8 mice per group). MCF7 and ZR751 combination studies, Fig. 5a and b.
View article: Additional file 5 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Additional file 5 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer Open
Additional file 5: Table S2. Pharmacodynamic changes in protein levels in acquired resistant cells versus parental cells. RPPA data (norm_Log2 values) restricted to the proteins with a > 0.25 or
View article: Additional file 6 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Additional file 6 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer Open
Additional file 6: Table S3. Pharmacodynamic changes in protein levels in xenografts responding to 50-100 mg/kg palbociclib prior to progression on treatment (resistant). Individual xenograft samples either from MCF7 vehicle treated mice, …
View article: Additional file 8 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Additional file 8 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer Open
Additional file 8: Table S5. Pharmacodynamic changes in protein levels in treated groups relative to vehicle control. As measured by RPPA. Normalized, median-centered log (expression) values were calculated for each sample, mean expression…
View article: Ribociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses
Ribociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses Open
Background: In the Phase III MONALEESA-3 study (NCT02422615), RIB + FUL significantly improved progression-free survival (PFS) vs placebo (PBO) + FUL in patients with HR+, HER2– ABC who received no or up to 1 line of prior endocrine therap…